|
0
|
|
Biomarker-driven strategy for early discontinuation of empirical antifungal treatment in critically ill patients: the role of (1-3)-beta-D-glucan using Wako(R) test.
(academic.oup.com)
|
Albanell-Fernandez M
…
Herrera S
Journal of Antimicrobial Chemotherapy
2026-07-02
|
#antifungal
#biomarker
#candidiasis
#stewardship
#diagnostics
|
|
0
|
|
Can pharmacokinetic/pharmacodynamic targets be achieved with voriconazole in the treatment of urinary tract infections caused by Candida spp. with reduced susceptibility to fluconazole?
(academic.oup.com)
|
Boglione-Kerrien C
…
Guegan H
Journal of Antimicrobial Chemotherapy
2026-07-02
|
#pharmacokinetics
#antifungal
#susceptibility
#candidiasis
#urinary
|
|
0
|
|
Evaluation of an early step-down (</=5 days) strategy from echinocandins to azole therapy for the treatment of invasive candidiasis.
(academic.oup.com)
|
Albanell-Fernandez M
…
Herrera S
Journal of Antimicrobial Chemotherapy
2026-07-02
|
#antifungal
#candidiasis
#de-escalation
#infection
|
|
0
|
|
Antifungal susceptibility profiles of clinical and environmental Scedosporium and Lomentospora isolates from Taiwan: focus on olorofim activity and phylogenetic heterogeneity.
(academic.oup.com)
|
Lin SY
…
Huang YT
Journal of Antimicrobial Chemotherapy
2026-07-02
|
#susceptibility
#antifungal
#amr
#mycology
#infection
|
|
0
|
|
Subtherapeutic posaconazole exposure during delayed-release tablet prophylaxis in high-risk patients with haematological malignancies: rationale for routine therapeutic drug monitoring.
(academic.oup.com)
|
Urbancic KF
…
Slavin MA
Journal of Antimicrobial Chemotherapy
2026-07-02
|
#antifungal
#therapeutic drug monitoring
#prophylaxis
#hematologic
#bioavailability
|